202 Efficacy and Tolerability of Dapoxetine in the Treatment of Chinese Patients With Premature Ejaculation
Abstract
Premature ejaculation (PE) remains one of the most common male sexual dysfunction, and is characterized by the loss or absence of ejaculatory control, marked distress or interpersonal difficulty as well as by a short intravaginal ejaculatory latency time (IELT). Dapoxetine is the first SFDA-approved pharmacological agent for PE in China. Clinical trials of dapoxetine reported in the literature have mainly been performed in Western populations. By comparison, there are far fewer studies on the efficacy and tolerability of dapoxetine in Chinese patients with PE. This study investigates the efficacy and tolerability of dapoxetine treatment in Chinese men with PE. This study was open and prospective in its design, and included patients treated in our hospital with dapoxetine from February 2014 to February 2015. All patients received dapoxetine 30mg prn (1–3 hours before sexual intercourse) for 4 weeks. Data on their IELT and Premature Ejaculation Profile (PEP) were recorded before and after the completion of dapoxetine treatment regimen. Data on the Clinical Global Impression of Change (CGIC) and treatment-emergent adverse events (TEAEs) were collected in the one-month follow-up after treatment completion.
Read the paper
Related studies
- Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial
- Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- A randomized, controlled trial of oral propranolol in infantile hemangioma
- Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study
- Increased physical activity improves sleep and mood outcomes in inactive people with insomnia: a randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.